Review pending. Every figure has been located on its cited source page in an AI-assisted source verification (matched to OCR text and compared cell by cell with the page image; read from the page image) (17 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review
Intravenous Infusions
On this page
Company details
- Legal name
- Intravenous Infusions PLC
- Listing
- IIL on the Ghana Stock Exchange, active (observed 2026-10-08)
- Sector
- Not classified (our classification from the stated principal activity)
- Financial year ends
- 31 December
Overview
Year ended 31 December 2025 · annual report, signed / final · source
Read with these figures
- Going-concern warning. The auditor's report for the year ended 31 December 2025 states a material uncertainty about whether the company can continue as a going concern.
- Company-only statements, not group results. These are Intravenous Infusions PLC's own (separate) statements; its 100% subsidiary FlexPharm Ltd is carried as 'Investment in subsidiary' at GHS 9,720 (p12, p32), and no consolidated statements are printed in this document or referred to as published.
Full wording and sources
Auditor's report, year to 2025-12-31: material uncertainty related to going concern
Emphasis of Matter - Going Concern: We draw attention to note 29 to the financial statements which indicates that the Company incurred a net loss of GHS4,631,793 during the year ended 31 December 2025. This condition indicates the existence of uncertainty which may cast doubt about the Company's ability to continue as a going concern. ... Our opinion is not modified in respect of this matter.
Source: Intravenous Infusions PLC Annual Report and Financial Statements for the year ended 31 December 2025, p7 (dated 2026-04-22)
Company-only statements, not group results
These are Intravenous Infusions PLC's own (separate) statements; its 100% subsidiary FlexPharm Ltd is carried as 'Investment in subsidiary' at GHS 9,720 (p12, p32), and no consolidated statements are printed in this document or referred to as published. The figures are the parent company's and are not group results.
Source: Intravenous Infusions PLC Annual Report and Financial Statements for the year ended 31 December 2025 (dated 2026-04-22)
-
Revenue
GHS 9.30 million
9,303,973 GHS units · p11
−62.7% vs 2024
-
Operating profit / (loss)
−GHS 5.67 million
(5,668,307) GHS units · p11
Change not shown.
-
Profit / (loss) for the year
−GHS 4.63 million
(4,631,793) GHS units · p11
Change not shown.
-
Total assets
GHS 39.1 million
39,093,687 GHS units · p12
−12.8% vs 2024
-
Total equity
GHS 11.3 million
11,279,089 GHS units · p12
−29.1% vs 2024
-
Cash from operations
−GHS 492,900
(492,900) GHS units · p14
−106.7% vs 2024
Large amounts are rounded for reading (GHS million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.
Not shown: the prior-year figure is zero or negative.
Financial statements
Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in GHS units unless the row says otherwise; brackets are negative.
† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table
Column sources
- FY2025 — annual report, signed / final; reported for the year · source
- FY2024 — annual report, signed / final; comparative in the FY2025 filing · source
Income statement
| Line (as printed) | FY2025Annual reportreported for the year | FY2024Annual reportcomparative in FY2025 filing |
|---|---|---|
| Revenue | 9,303,973 | 24,940,063 |
| Cost of sales | (7,994,850) | (13,390,855) |
| Gross profit | 1,309,123 | 11,549,208 |
| Other income | 58,751 | 825,423 |
| Operating and other expenses | (8,712,141) | (10,073,843) |
| Other gains and (losses)1 | 2,229,891 | (1,984,831) |
| Depreciation | (548,512) | (652,455) |
| Amortization | (5,419) | (5,419) |
| (Loss) / profit before interest and tax (PBIT) | (5,668,307) | (341,917) |
| Finance costs | (110,357) | (143,381) |
| Loss before tax | (5,778,664) | (485,298) |
| Income tax expense | 1,146,871 | (157,590) |
| Loss for the year | (4,631,793) | (642,888) |
| Other Comprehensive Income | –2 | –2 |
| Total Comprehensive Income | (4,631,793) | (642,888) |
- Printed “-”, read as nil: subtotal_arithmetic: is.total_comprehensive_income.
Notes and alternative reported figures (1)
- “Other gains and (losses)” is an issuer-specific line, not mapped to a shared definition: Other gains and losses, printed after operating and other expenses (p11).
Balance sheet
| Line (as printed) | FY2025Annual reportreported for the year | FY2024Annual reportcomparative in FY2025 filing |
|---|---|---|
| Property, plant and equipment | 25,875,371 | 24,496,157 |
| Intangible assets | 63,082 | 68,502 |
| Investment in subsidiary1 | 9,720 | 9,720 |
| Deferred tax assets | 595,608 | –2 |
| Non-current assets (unlabelled subtotal) | 26,543,781 | 24,574,379 |
| Inventories | 4,531,046 | 6,085,219 |
| Trade and other receivables | 7,269,570 | 12,229,266 |
| Current tax asset | 728,403 | 462,288 |
| Cash and cash equivalents | 20,887 | 1,485,711 |
| Current assets (unlabelled subtotal) | 12,549,906 | 20,262,484 |
| Total assets | 39,093,687 | 44,836,863 |
| Stated capital | 11,626,451 | 11,626,451 |
| Capital Surplus3 | 2,103,120 | 2,103,120 |
| Retained Earnings | (2,450,482) | 2,181,311 |
| Total equity (unlabelled subtotal) | 11,279,089 | 15,910,882 |
| Deferred tax liabilities | –4 | 551,263 |
| Right-of-use obligation | 34,271 | 34,276 |
| Borrowings | 5,354,903 | 3,938,978 |
| Non-current liabilities (unlabelled subtotal) | 5,389,174 | 4,524,517 |
| Trade and other payables | 18,059,444 | 19,582,216 |
| Borrowings | 3,944,965 | 3,944,965 |
| Loan from directors5 | 421,015 | 874,283 |
| Current liabilities (unlabelled subtotal) | 22,425,424 | 24,401,464 |
| Total liabilities | 27,814,598 | 28,925,981 |
| Total equity and liabilities | 39,093,687 | 44,836,863 |
- Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_assets.
- Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_liabilities.
Notes and alternative reported figures (3)
- “Investment in subsidiary” is an issuer-specific line, not mapped to a shared definition: Note 14: 100% of FlexPharm Ltd at cost (GHS 9,720), not consolidated.
- “Capital Surplus” is an issuer-specific line, not mapped to a shared definition: Note 19: capital surplus (equity reserve), printed apart from stated capital.
- “Loan from directors” is an issuer-specific line, not mapped to a shared definition: Note 24: loans from directors, current liabilities.
Cash flow
| Line (as printed) | FY2025Annual reportreported for the year | FY2024Annual reportcomparative in FY2025 filing |
|---|---|---|
| Net cash flows (used in) / from operations | (76,785) | 7,959,504 |
| Dividend paid | (150,000) | (100,000) |
| Income taxes paid | (266,115) | (463,021) |
| Net cash flows (used in) / from operating activities | (492,900) | 7,396,483 |
| Transfer of property, plant and equipment1 | 18,006 | 12,555 |
| Purchase of property, plant and equipment | (529,807) | (1,901,510) |
| Purchase of intangible assets | –2 | (4,000) |
| Cash flows used in investing activities | (511,801) | (1,892,955) |
| Repayment of lease liability | (6,855) | (6,855) |
| Borrowings repayment | –3 | (3,944,965) |
| Loan repayment to directors4 | (459,300) | (712,366) |
| Forex echange loss/gain5 | 6,032 | 245,009 |
| Accrued interest6 | –3 | 107,727 |
| Cash flows used in financing activities | (460,123) | (4,311,450) |
| Net (decrease) / increase in cash and cash equivalents | (1,464,824) | 1,192,078 |
| Cash and cash equivalents at beginning of the year | 1,485,711 | 293,633 |
| Cash and cash equivalents at end of the year | 20,887 | 1,485,711 |
- Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_investing.
- Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_financing.
Notes and alternative reported figures (4)
- “Transfer of property, plant and equipment” is an issuer-specific line, not mapped to a shared definition: Investing inflow printed as 'Transfer of property, plant and equipment' (p14).
- “Loan repayment to directors” is an issuer-specific line, not mapped to a shared definition: Repayment of directors' loans, financing activities (p14).
- “Forex echange loss/gain” is an issuer-specific line, not mapped to a shared definition: Exchange difference printed within financing activities (label as printed, p14).
- “Accrued interest” is an issuer-specific line, not mapped to a shared definition: Accrued interest printed within financing activities (p14).
Reported measures outside the statements
| Measure (as printed) | FY2025 | FY2024 |
|---|---|---|
| (Loss) / profit before depreciation, interest and tax (PBDIT) | (5,114,376) p11 | 315,957 p11 |
Segments
Segment data not yet collected for this company in the pilot.
Dividends
Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.
| Year ended | Event | Wording as printed | Amount | Unit | Source |
|---|---|---|---|---|---|
| 31 Dec 2025 | Dividends paid (cash flow statement) | Dividend paid |
(150,000) | GHS units | Annual report, p14 |
| 31 Dec 2024 | Dividends paid (cash flow statement) | Dividend paid |
(100,000) | GHS units | Annual report, p14 |
Sources
Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.
-
Intravenous Infusions PLC Annual Report and Financial Statements for the year ended 31 December 2025
Year ended 31 December 2025 · Annual report · signed / final
Audit: Intellisys (Chartered Accountants), unmodified opinion · signed · includes a material-uncertainty paragraph
Auditor's sign-off: Intellisys (engagement partner MyraStella Ansah, ICAG/P/1438)
Final status: Independent auditor's report of Intellisys (ICAG/F/2026/078), engagement partner MyraStella Ansah (ICAG/P/1438), unmodified opinion with an emphasis of matter on going concern (PDF p7-8); signed by hand in the firm's name with the firm's stamp and dated by hand 22nd April 2026 (PDF p10, render). Statements approved by the Board of Directors and signed by two directors (hand signatures, names not printed), dated by hand 22/04/2026 (PDF p12).
- Document date
- 22 Apr 2026
- Auditor's report
- 22 Apr 2026
- Board approval
- 22 Apr 2026
- Retrieved by us
- 8 Oct 2026 (not a publication date)
- Used for
- statement columns FY2025, FY2024
- Basis
- company statements · GHS units (printed “Figures in GHS”)
- EPS is printed as 'Basic earnings/(loss) per ordinary share (pesewa)' (0.0169) and (0.0023), but the figures match a cedi amount per share (loss GHS4.6m over about 274m shares); not transcribed because the printed unit and the figure disagree (p11). Dividend paid is presented within operating activities (p14).
- SEPARATE COMPANY STATEMENTS ONLY: the company holds 100% of FlexPharm Ltd (investment in subsidiary GHS 9,720, note 14 p29; p32), carried at cost. No consolidated statements are printed or mentioned; the auditor's opinion covers the Company's statements (p7).
Technical details
- File
- 34 pages, scanned (figures read by OCR and checked against the page image)
- SHA-256
db6ada7f03981f4ff4d122dd9ab1c2e42a828320f96c7a1fca5e18b37ab9a2ec- Entity as printed
- Intravenous Infusions PLC
- Note
- Every page is a scanned image without a text layer. OCR fixes: 825.423, (8.712,141), 315.957, 7.959,504 and 107.727 (full stops read for thousands commas). Dashes OCR does not return were read on the render.
- Exchange copy
- retrieved 2026-10-08T17:52:13Z
Data notes
- Other income — OCR read '825.423'; the page image shows '825,423'. Other income 2024: OCR reads a full stop for the thousands comma; the render shows 825,423. (Intravenous Infusions PLC Annual Report and Financial Statements for the year ended 31 December 2025, p11)
- Operating and other expenses — OCR read '(8.712,141)'; the page image shows '(8,712,141)'. Operating and other expenses 2025: OCR reads a full stop for the first comma; the render shows (8,712,141). (Intravenous Infusions PLC Annual Report and Financial Statements for the year ended 31 December 2025, p11)
- (Loss) / profit before depreciation, interest and tax (PBDIT) — OCR read '315.957'; the page image shows '315,957'. PBDIT 2024: OCR reads a full stop for the thousands comma; the render shows 315,957. (Intravenous Infusions PLC Annual Report and Financial Statements for the year ended 31 December 2025, p11)
- Net cash flows (used in) / from operations — OCR read '7.959,504'; the page image shows '7,959,504'. Net cash flows from operations 2024: OCR reads a full stop for the first comma; the render shows 7,959,504. (Intravenous Infusions PLC Annual Report and Financial Statements for the year ended 31 December 2025, p14)
- Accrued interest — OCR read '107.727'; the page image shows '107,727'. Accrued interest 2024: OCR reads a full stop for the thousands comma; the render shows 107,727. (Intravenous Infusions PLC Annual Report and Financial Statements for the year ended 31 December 2025, p14)
Review status: every figure has been located on its cited source page in an AI-assisted source verification (matched to OCR text and compared cell by cell with the page image; read from the page image) (17 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.
Download
Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.